Latest 8-K filings

InTest Corporation announced strong second quarter 2026 financial results, with revenue up 25.5% year-over-year to $35.3 million, driven by the Auto/EV market.

Replimune Group, Inc. announced the pricing of an underwritten offering of common stock and pre-funded warrants, raising approximately $150 million.

AbCellera Biologics Inc. announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635, showing significant reductions in vasomotor symptoms and a favorable tolerability profile.

Athene Holding Ltd. released its Q2 2026 financial supplement, showcasing robust growth in net invested assets and spread-related earnings, alongside a significant increase in total assets.

Aeries Technology announced a 43% year-over-year revenue increase to $21.9 million for the quarter ended June 30, 2026, alongside significant improvements in profitability and the launch of its AxAI solution.

Sharplink, Inc. reported a substantial net loss of $394.3 million for Q2 2026, primarily driven by non-cash unrealized losses and impairments on its Ether holdings, despite a significant increase in total revenue to $11.5 million.

Jazz Pharmaceuticals announced its definitive agreement to acquire Actio Biosciences for $820 million upfront, plus up to $500 million in contingent consideration, to expand its rare epilepsy portfolio with the addition of ABS-1230.

Sonida Senior Living announced robust second quarter 2026 financial results, highlighting significant occupancy gains, NOI growth, and strategic debt management.

SunocoCorp LLC announced its participation in upcoming industry conferences, signaling active engagement with the investment community.

L.B. Foster Company announced second quarter 2026 results, featuring record operating cash flow and significant debt reduction, while reaffirming full-year financial guidance.

Sunoco LP announced its participation in the 2026 Citi Natural Resources Conference and the Barclays 40th Annual Energy-Power Conference, with senior management set to engage with the investment community.

GCM Grosvenor announced robust second quarter 2026 financial results, highlighted by a 21% year-over-year increase in Fee-Related Earnings and a 22% rise in Adjusted Net Income, alongside a 13% growth in Assets Under Management.

Varex Imaging announced third quarter fiscal year 2026 results, showing a 4% year-over-year revenue increase to $210.5 million, driven by strong industrial segment growth, alongside improved gross margins.

Surgery Partners announced its second quarter 2026 financial results, reporting a 2.7% increase in revenue and reaffirming its full-year guidance, despite a net loss for the quarter.

International Seaways announces record-breaking second quarter 2026 results, including record net income, adjusted EBITDA, and free cash flow, alongside a historic dividend declaration.

Silence Therapeutics plc announced its second quarter 2026 financial and business results, highlighting progress in its Divesiran and SLN312 programs and a reduced net loss.

Apogee Therapeutics announced its second quarter 2026 financial results, highlighting positive Phase 2 trial data for zumilokibart and a definitive agreement to be acquired by AbbVie for approximately $10.9 billion.

Liberty Media Corporation announced its intention to offer $600 million in convertible senior notes due 2032, with an option for an additional $90 million, to manage existing debt and fund general corporate purposes.

Tenax Therapeutics announced topline results from its Phase 3 LEVEL trial of TNX-103 for PH-HFpEF, which did not meet its primary endpoint for improving 6-minute walk distance.

Tonix Pharmaceuticals announced robust second-quarter 2026 financial results, highlighted by a significant increase in TONMYA net sales and progress across its clinical development pipeline.

MoonLake Immunotherapeutics reported positive topline results from its Phase 3 IZAR-1 trial for sonelokimab in psoriatic arthritis, alongside its second quarter 2026 financial results.

Sionna Therapeutics announced topline data from its SION-719 Phase 2a trial did not meet its primary endpoint, leading to the decision not to advance the drug as an add-on therapy, while also providing an update on its SION-451 program.

Jade Biosciences announced positive interim Phase 1 data for JADE101, a potential best-in-class therapy for IgA nephropathy, and provided a corporate update highlighting a strong cash runway into late 2028.

SIFCO Industries announced robust financial results for its third quarter and first nine months of fiscal 2026, showcasing substantial increases in net sales and a significant turnaround in profitability.

AAON, Inc. announced record second quarter 2026 results, driven by a 101.2% increase in net sales to $627.0 million, significant growth in operating income and EPS, and a raised full-year financial outlook.

Ceva, Inc. announced its second quarter 2026 financial results, highlighting a 13% year-over-year revenue increase driven by a three-year high in licensing and related revenues.

News Corporation has provided an update on its ongoing stock repurchase program, detailing recent buyback activity for its Class A and Class B common stock.

Shoulder Innovations, Inc. announced the promotion of Jon Osborne to Chief Commercial Officer, effective August 6, 2026, to lead commercial strategy and execution.

OPAL Fuels announced solid second quarter 2026 results, with Adjusted EBITDA up 40% year-over-year, driven by 45Z production tax credits and FSS segment growth, while maintaining annual guidance.

Aquestive Therapeutics announced positive topline results from human factors and pharmacokinetic studies for its Anaphylm sublingual film, supporting a planned New Drug Application resubmission to the FDA.